Analiza finansowania programów lekowych w latach 2016–2024 jako istotnego elementu dostępu do świadczeń lekowych w Polsce

Michał Seweryn; Anna Łuc-Seweryn; Anna Mokrzycka; Elżbieta Gabrowska; Sławomir Kozioł; Wojciech Trąbka

doi:10.48269/2451-0858-pis-2025-2-010

Published: 2025-12-31

Vol. 25 No. 2 (2025)

Analysis of the financing of drug programs in 2016–2024 as an important component of access to drug therapies in Poland

Michał Seweryn

, Anna Łuc-Seweryn

, Anna Mokrzycka

, Elżbieta Gabrowska

, Sławomir Kozioł

, Wojciech Trąbka

Section: Health Sciences

https://doi.org/10.48269/2451-0858-pis-2025-2-010

Abstract

Introduction and objective: Drug programs are a key instrument of reimbursement policy in Poland, enabling the public financing of innovative and high-cost therapies in strictly defined patient populations. The aim of this study was to analyze the financing of drug programs in Poland in 2016–2024 as an element of reimbursement and health policy.
Material and methods: A retrospective descriptive analysis of secondary data was conducted using the Minister of Health’s Reimbursement Notices and aggregated data from the System and Implementation Analyses Database. Changes in the scale of programs and the number of patients were assessed, as well as expenditures (medicines, services) and discrepancies between reported and settled amounts.
Results: In 2016–2024, the number of programs increased from 73 to 133, the number of active substances from 161 to 392, and the number of patients from 105.6 thousand to 302.1 thousand. Total costs rose from PLN 3,157 billion to PLN 12,547 billion; cost per patient increased from PLN 29,896 to PLN 41,533, and the share of service costs grew from 8.1% to 11.4%. In 2024, 95.37% of reported amounts were settled (a gap of PLN 613.8 million).
Conclusions: Financing of drug programs grew faster than treatment volume, and the increasing share of service costs indicates a greater role of diagnostics and monitoring. The widening reported–settled gap may threaten the liquidity of providers (hospitals) and requires systematic monitoring.

Keywords:

drug programs , reimbursement policy , public expenditure , health policy

Download files

PDF (Język polski)

Citation rules

Seweryn, Michał, et al. “Analysis of the Financing of Drug Programs in 2016–2024 As an Important Component of Access to Drug Therapies in Poland”. State & Society, vol. 25, no. 2, Dec. 2025, pp. 123-35, doi:10.48269/2451-0858-pis-2025-2-010.

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

Mela A, Poniatowski ŁA, Drop B, Furtak-Niczyporuk M, Jaroszyński J, Wrona W, Staniszewska A, Dabrowski J, Czajka A, Jagielska B, Wojciechowska M, Niewada M. Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years. Front Pharmacol. 2020;11:1123, https://doi.org/10.3389/fphar.2020.01123.
Google Scholar

Seweryn M, Koperny M, Drobisz-Miętkiewicz A. Finansowanie najdroższych terapii lekowych w Polsce a problemy w dostępie do nich. Analiza poziomu finansowania i opłacalności programów terapeutycznych. Zdrowie Publiczne i Zarządzanie.
Google Scholar

2011;9(2):97–104.
Google Scholar

Golinowska S, Sowada C, Tambor M, Dubas K, Jurkiewicz-Świętek I, Kocot E, Seweryn M, Evetovits T. Równowaga finansowa oraz efektywność w polskim systemie ochrony zdrowia. Problemy i wyzwania. Fundacja Zdrowia Publicznego. Uniwersyteckie Wydawnictwo Medyczne „Vesalius”, Kraków 2012.
Google Scholar

Ministerstwo Zdrowia. Obwieszczenia ministra zdrowia – lista leków refundowanych; https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych [dostęp: 15.11.2025].
Google Scholar

Ministerstwo Zdrowia. Baza Analiz Systemowych i Wdrożeniowych. Programy lekowe; https://basiw.mz.gov.pl/mapy-informacje/mapa-2022-2026/analizy/programy-lekowe/ [dostęp: 18.11.2025].
Google Scholar

Rogowski W, Zyśk R, Krzakowski M. Programy lekowe w onkologii. Jak optymalnie wykorzystać ich możliwości?. Onkol Prakt Klin Edu. 2018;4(5):321–333, https://doi.org/10.5603/owpk_edu.61495.
Google Scholar

Jahnz-Różyk K, Kawalec P, Malinowski K, Czok K. Drug Policy in Poland. Value Health Reg Issues. 2017;13:23–26, https://doi.org/10.1016/j.vhri.2017.07.001.
Google Scholar

Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuolienè K, Haycox A, Garattini S, Gustafsson LL. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC
Google Scholar

Health Serv Res. 2010;10:153, https://doi.org/10.1186/1472-6963-10-153.
Google Scholar

Futyma K, Śliwczyński A. A preliminary model for assessing real costs incurred by a healthcare entity in connection with the implementation of an oncological drug programme. Med Og Nauk Zdr. 2022;28(2):149–156, https://doi.org/10.26444/monz/150619.
Google Scholar

Jassem J, Krzakowski M, Chorostowska J, Duchnowska R, Czech M, Dziadziuszko R, Hus I, Kubiatowski T, Potemski P, Radecka B, Rutkowski P, Wysocki P, Zaucha JM, Jakubiak K. Programy lekowe w onkologii: rekomendacje zmian. Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY. 2022;7(2):150–153.
Google Scholar

Vol. 25 No. 2 (2025)
Published: 2025-12-31

ISSN: 1643-8299

eISSN: 2451-0858

10.31749/2451-0718-SaS

Publisher

AFM Publishing House of the Andrzej Frycz Modrzewski Krakow University

Licence CC

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Submit